Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle, Stefan K Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P Plastaras, Amit Maity, Agata M Bogusz, Stacy S Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J Schuster, Jakub Svoboda, Steven M Bair, Daniel J Landsburg, Sunita Dwivedy Nasta, Sarah J Nagle, Stefan K Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren Strelec, Elise Chong, Sheryl Mitnick, Terease S Waite, Cara King, Hatcher Ballard, Matthew Youngman, James Gerson, John P Plastaras, Amit Maity, Agata M Bogusz, Stacy S Hung, Hisae Nakamura, Reza Nejati, Christian Steidl, Megan Lim, Marco Ruella, Stephen J Schuster
Abstract
We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22 with primary mediastinal B-cell lymphoma (PMBCL), 5 with diffuse large B-cell lymphoma (DLBCL), and 2 with gray zone lymphoma (GZL). There were no treatment-related deaths; 32% of patients had non-hematological grade 3/4 toxicities. The overall response rate was 100% (95% CI: 88-100) with 86% (95% CI: 68-96) of patients achieving complete response at the end of systemic treatment. Consolidative radiation following end of treatment response assessment was permissible and used in 52% of all patients including 59% of patients with PMBCL. With a median follow-up of 30 months, the 2-year progression-free survival (PFS) and overall survival (OS) were 85% (95% CI: 66-94) and 100%, respectively. In the PMBCL cohort, 2-year PFS was 86% (95% CI: 62-95). In summary, BV-R-CHP with or without consolidative radiation is a feasible and active frontline regimen for CD30+ B-cell lymphomas (NCT01994850).
Figures
References
- Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11:19.
- Younes A, Gopal AK, Smith SE, et al. . Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189.
- Pro B, Advani R, Brice P, et al. . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
- Connors JM, Jurczak W, Straus DJ, et al. . Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331-344.
- Horwitz S, O'Connor OA, Pro B, et al. . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, doubleblind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240.
- Hu S, Xu-Monette ZY, Balasubramanyam A, et al. . CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-2724.
- Lu T-X, Liang J-H, Miao Y, et al. . Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015;5:12168.
- Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia. Br J Haematol. 2014;167(5):608-617.
- Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999;112(2):241-247.
- Barth TF, Leithauser F, Joos S, Bentz M, Moller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3(4):229-234.
- Rosenwald A, Wright G, Leroy K, et al. . Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
- Mottok A, Steidl C. Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies. Blood. 2018;131(15):1654-1665.
- Zinzani PL, Stefoni V, Finolezzi E, et al. . Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381-385.
- Rieger M, Österborg A, Pettengell R, et al. . Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2010;22(3):664-670.
- Dunleavy K, Pittaluga S, Maeda LS, et al. . Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
- Gleeson M, Hawkes EA, Cunningham D, et al. . Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (RCHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. Br J Haematol. 2016;175(4):668-672.
- Bartlett NL, Wilson WH, Jung S-H, et al. . Dose-adjusted EPOCH-R compared with RCHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol;2019; 37(21):1790-1799.
- Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329-1336.
- Giulino-Roth L, O'Donohue T, Chen Z, et al. . Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739-747.
- Armand P, Rodig SJ, Melnichenko V, et al. . Pembrolizumab in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL): data from the Keynote-013 and Keynote-170 studies. Blood. 2018;132(Suppl 1):228.
- Neelapu SS, Locke FL, Bartlett NL, et al. . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
- Zinzani PL, Ribrag V, Moskowitz CH, et al. . Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267-270.
- Moskowitz AJ, Santoro A, Gritti G, et al. . Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: preliminary results from the phase 2 CheckMate 436 trial. Blood. 2018;132(Suppl 1):1691.
- Zinzani PL, Pellegrini C, Chiappella A, et al. . Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood. 2017;129(16):2328-2330.
- Cheson BD, Pfistner B, Juweid ME, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586.
- Mottok A, Wright G, Rosenwald A, et al. . Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood. 2018;132(22):2401-2405.
- Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343-346.
- International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
- Jacobsen ED, Sharman JP, Oki Y, et al. . Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394-1402.
- Shah NN, Szabo A, Huntington SF, et al. . RCHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534-544.
- Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55(3):538-543.
- Martelli M, Ceriani L, Zucca E, et al. . [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32(17):1769-1775.
- Bartlett NL, Farber CM, Yasenchak CA, et al. . Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large Bcell lymphoma (DLBCL). J Clin Oncol. 2015;33(15_suppl):8506.
- Vitolo U, Trněný M, Belada D, et al. . Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;35(31):3529-3537.
- Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma. Thromb Res. 2010;126(6): 477-480.
- Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759-3765.
- Kim YH, Prince HM, Whittaker S, et al. . Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician's choice (PC) in the phase 3 ALCANZA study. J Clin Oncol. 2017;35(15_suppl):7517.
- Sabattini E, Pizzi M, Tabanelli V, et al. . CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-e82.
Source: PubMed